OptimizeRx Corporation (OPRX) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
OptimizeRx Corporation (OPRX) Bundle
Optimize your time and improve precision with our OptimizeRx Corporation (OPRX) DCF Calculator! Equipped with authentic data and customizable assumptions, this tool enables you to forecast, analyze, and evaluate OptimizeRx Corporation (OPRX) just like a seasoned investor.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 24.6 | 43.3 | 61.3 | 62.5 | 71.5 | 95.5 | 127.5 | 170.2 | 227.2 | 303.3 |
| Revenue Growth, % | 0 | 76.08 | 41.51 | 1.89 | 14.53 | 33.5 | 33.5 | 33.5 | 33.5 | 33.5 |
| EBITDA | -2.8 | -.1 | 2.3 | -9.4 | -21.3 | -10.0 | -13.4 | -17.8 | -23.8 | -31.8 |
| EBITDA, % | -11.21 | -0.13721 | 3.8 | -15.08 | -29.79 | -10.48 | -10.48 | -10.48 | -10.48 | -10.48 |
| Depreciation | 1.3 | 2.1 | 2.1 | 2.0 | 2.4 | 3.8 | 5.1 | 6.8 | 9.1 | 12.1 |
| Depreciation, % | 5.21 | 4.79 | 3.4 | 3.24 | 3.36 | 4 | 4 | 4 | 4 | 4 |
| EBIT | -4.0 | -2.1 | .2 | -11.4 | -23.7 | -13.8 | -18.5 | -24.7 | -32.9 | -43.9 |
| EBIT, % | -16.43 | -4.93 | 0.39152 | -18.32 | -33.15 | -14.49 | -14.49 | -14.49 | -14.49 | -14.49 |
| Total Cash | 18.9 | 10.5 | 84.7 | 74.1 | 13.9 | 61.2 | 81.7 | 109.0 | 145.5 | 194.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 7.4 | 17.9 | 24.8 | 22.2 | 37.3 | 38.1 | 50.9 | 67.9 | 90.7 | 121.0 |
| Account Receivables, % | 30.16 | 41.29 | 40.46 | 35.48 | 52.14 | 39.91 | 39.91 | 39.91 | 39.91 | 39.91 |
| Inventories | .0 | .0 | -5,630,649.4 | 1.8 | .0 | -18.5 | -24.8 | -33.1 | -44.1 | -58.9 |
| Inventories, % | 0 | 0 | -9186507.92 | 2.89 | 0 | -19.42 | -19.42 | -19.42 | -19.42 | -19.42 |
| Accounts Payable | .5 | .6 | .6 | 1.5 | 2.2 | 1.9 | 2.6 | 3.4 | 4.6 | 6.1 |
| Accounts Payable, % | 2 | 1.43 | 0.99002 | 2.48 | 3.11 | 2 | 2 | 2 | 2 | 2 |
| Capital Expenditure | -1.6 | -.1 | -.5 | -.2 | -.9 | -1.7 | -2.3 | -3.1 | -4.2 | -5.5 |
| Capital Expenditure, % | -6.45 | -0.28796 | -0.79292 | -0.39162 | -1.22 | -1.83 | -1.83 | -1.83 | -1.83 | -1.83 |
| Tax Rate, % | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 | 30.19 |
| EBITAT | -3.1 | -2.3 | .2 | -10.6 | -16.6 | -11.4 | -15.2 | -20.3 | -27.2 | -36.3 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -10.4 | -10.7 | 5,630,644.2 | -5,630,656.4 | -27.7 | 8.1 | -18.4 | -24.5 | -32.8 | -43.7 |
| WACC, % | 8.53 | 8.82 | 8.46 | 8.72 | 8.42 | 8.59 | 8.59 | 8.59 | 8.59 | 8.59 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -79.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -45 | |||||||||
| Terminal Value | -677 | |||||||||
| Present Terminal Value | -448 | |||||||||
| Enterprise Value | -528 | |||||||||
| Net Debt | 23 | |||||||||
| Equity Value | -551 | |||||||||
| Diluted Shares Outstanding, MM | 17 | |||||||||
| Equity Value Per Share | -32.19 |
What You Will Receive
- Adjustable Forecast Inputs: Effortlessly modify assumptions (growth %, margins, WACC) to explore various scenarios.
- Comprehensive Data: OptimizeRx Corporation’s financial information pre-loaded to facilitate your analysis.
- Instant DCF Outputs: The template computes Net Present Value (NPV) and intrinsic value automatically.
- Tailored and Professional: A refined Excel model that customizes to fit your valuation requirements.
- Designed for Analysts and Investors: Perfect for evaluating projections, confirming strategies, and streamlining your workflow.
Key Features
- Comprehensive DCF Calculator: Features in-depth unlevered and levered DCF valuation models tailored for OptimizeRx Corporation (OPRX).
- WACC Calculator: Comes with a pre-configured Weighted Average Cost of Capital sheet that allows for customizable inputs.
- Adjustable Forecast Assumptions: Easily alter growth rates, capital expenditures, and discount rates to fit your analysis.
- Integrated Financial Ratios: Evaluate profitability, leverage, and efficiency ratios specifically for OptimizeRx Corporation (OPRX).
- User-Friendly Dashboard and Charts: Visual representations of key valuation metrics facilitate straightforward analysis.
How It Works
- 1. Access the Template: Download and open the Excel file containing OptimizeRx Corporation's (OPRX) financial data.
- 2. Adjust Key Inputs: Modify essential parameters such as revenue growth, discount rates, and investment expenditures.
- 3. See Immediate Results: The DCF model automatically computes the intrinsic value and net present value (NPV).
- 4. Explore Different Scenarios: Analyze various forecasts to evaluate multiple valuation possibilities.
- 5. Present with Assurance: Deliver expert valuation analyses to bolster your strategic decisions.
Why Choose This Calculator for OptimizeRx Corporation (OPRX)?
- Designed for Experts: A sophisticated tool utilized by financial analysts, CFOs, and industry consultants.
- Accurate Financial Data: OptimizeRx’s historical and forecasted financials are preloaded for precision.
- Forecast Simulation: Effortlessly test various scenarios and assumptions.
- Comprehensive Results: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance simplifies the entire process.
Who Should Use This Product?
- Investors: Accurately assess OptimizeRx Corporation’s (OPRX) fair value prior to making investment decisions.
- CFOs: Utilize a professional-grade DCF model for financial reporting and analysis related to OptimizeRx Corporation (OPRX).
- Consultants: Efficiently customize the template for valuation reports for clients involving OptimizeRx Corporation (OPRX).
- Entrepreneurs: Acquire insights into financial modeling practices employed by leading healthcare companies, including OptimizeRx Corporation (OPRX).
- Educators: Implement it as a teaching resource to illustrate valuation methodologies with a focus on OptimizeRx Corporation (OPRX).
What the Template Contains
- Preloaded OPRX Data: Historical and projected financial data, including revenue, EBIT, and capital expenditures.
- DCF and WACC Models: Professional-grade sheets for calculating intrinsic value and Weighted Average Cost of Capital.
- Editable Inputs: Yellow-highlighted cells for adjusting revenue growth, tax rates, and discount rates.
- Financial Statements: Comprehensive annual and quarterly financials for deeper analysis.
- Key Ratios: Profitability, leverage, and efficiency ratios to evaluate performance.
- Dashboard and Charts: Visual summaries of valuation outcomes and assumptions.